Adalimumab 40mg/0.4ml solution for injection pre-filled disposable devices
Requires a prescription from a doctor or prescriber
Drugs used in rheumatic diseases and gout
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Adalimumab
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Adalimumab
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
5 branded products available
MHRA licensed products
View all licensed products for Adalimumab on the MHRA register
Amgevita HCF 40mg/0.4ml solution for injection pre-filled pens
Humira 40mg/0.4ml solution for injection pre-filled pens
Hyrimoz 40mg/0.4ml solution for injection pre-filled pens
Imraldi 40mg/0.4ml solution for injection pre-filled pens
Yuflyma 40mg/0.4ml solution for injection pre-filled pens
WHO defined daily dose (DDD)
2.9 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via NHS dm+d BNF mapping files. Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Clinical guidelines and formulary information
British National Formulary
Adalimumab
Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.
NICE clinical guidance(15)
Adalimumab for treating moderate to severe plaque psoriasis (TA146)
Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)
Adalimumab and dexamethasone for treating non-infectious uveitis (TA460)
Infliximab and adalimumab for the treatment of Crohn's disease (TA187)
Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (TA199)
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (TA455)
Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (TA373)
Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed (TA715)
Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (TA329)
Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (TA195)
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (TA375)
Crohn's disease: management (NG129)
Secukinumab for treating moderate to severe plaque psoriasis in children and young people (TA734)
Tofacitinib for treating juvenile idiopathic arthritis (TA735)
Golimumab for treating active non-radiographic axial spondyloarthritis (TA497)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & product information
Official product databases and supply status monitoring
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
10 to 20 days
Mechanism
Adalimumab binds with specificity to tumor necrosis factor-alpha (TNF-alpha) and…
Food interactions
None known
Human targets
1 target
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
1.6 μg/mL
Half-life
2 weeks
[L35370]
Volume of distribution
4.7 to 6.0 L
Elimination
[A40006]
Clearance
0.25 to 10 mg/k
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Several biosimilars to adalimumab. Adalimumab-atto was the first adalimumab biosimilar approved by the FDA in 2016.[L44953] Adalimumab-adaz was approved by the FDA on October 31, 2018.[L4799] Other biosimilars include adalimumab-fkjp - which was approved in July 2022 -,[L42495] adalimumab-bwwd - which was approved in August 2022 -,[L42935], adalimumab-aacf - which was approved in October 2023 [L49101] and adalimumab-ryvk - which was approved in February 2024[L52088]. A biosimilar marketed as Hyrimoz, a high-concentration formulation of adalimumab, is also available.[L45643][L45818]. A high-concentration, citrate-free formulation of Cyltezo® (adalimumab-adbm), a biosimilar to Humira®, was approved by the FDA in May 2024 for the treatment of multiple chronic inflammatory diseases.[L53083]
- Moderately to severely active Rheumatoid Arthritis (RA) in adults, as monotherapy or in combination with [methotrexate] or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs).
[L42290][L42495][L42935][L44953][L45643][L45818][L49101]
- Moderately to severely active polyarticular Juvenile Idiopathic Arthritis (JIA) in patients two years of age and older, as monotherapy or in combination with [methotrexate].
[L42290][L42495][L42935][L44953][L45643][L45818][L49101]
- Psoriatic Arthritis (PsA) in adults.
[L42290][L42495][L42935][L44953][L45643][L45818][L49101]
- Ankylosing Spondylitis (AS) in adults.
[L42290][L42495][L42935][L44953][L45643][L45818][L49101]
- Moderately to severely active Crohn’s Disease (CD) in adults and pediatric patients six years of age and older.
[L42290][L42495][L42935][L44953][L45643][L45818][L49101]
- Moderately to severely active Ulcerative Colitis (UC) in adults. Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers.
[L42290][L42495][L42935][L44953][L45643][L45818][L49101]
- Moderate to severe chronic plaque psoriasis in adult candidates for systemic therapy or phototherapy and when other systemic therapies are medically less appropriate.
[L42290][L42495][L42935][L44953][L45643][L45818][L49101]
- Moderate to severe Hidradenitis Suppurativa (HS) in adults.
[L44953]
- Non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients two years of age and older.
[L35370]
Adalimumab has also been used off-label to treat Pyoderma gangrenosum.
[A40001][A40002]
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 1361 interactions
[L42290]
How the body processes this drug — absorption, distribution, metabolism, and elimination
[L35370]
[L35370]
[L35370]
[A40006]
[L35370]
Proteins and enzymes this drug interacts with in the body
Impairs regulatory T-cells (Treg) function in individuals with rheumatoid arthritis via FOXP3 dephosphorylation. Up-regulates the expression of protein phosphatase 1 (PP1), which dephosphorylates the key 'Ser-418' residue of FOXP3, thereby inactivating FOXP3 and rendering Treg cells functionally defective .
PMID:23396208
Key mediator of cell death in the anticancer action of BCG-stimulated neutrophils in combination with DIABLO/SMAC mimetic in the RT4v6 bladder cancer cell line .
PMID:16829952 PMID:22517918 PMID:23396208
Induces insulin resistance in adipocytes via inhibition of insulin-induced IRS1 tyrosine phosphorylation and insulin-induced glucose uptake. Induces GKAP42 protein degradation in adipocytes which is partially responsible for TNF-induced insulin resistance (By similarity).
Plays a role in angiogenesis by inducing VEGF production synergistically with IL1B and IL6 .
PMID:12794819
Promotes osteoclastogenesis and therefore mediates bone resorption (By similarity)
ATC L04AB04
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Adalimumab
Additional database identifiers
Drugs Product Database (DPD)
13356
HUGO Gene Nomenclature Committee (HGNC)
HGNC:11892
GenAtlas
TNF
GeneCards
TNF
GenBank Gene Database
M16441
GenBank Protein Database
339741
UniProt Accession
TNFA_HUMAN
International reference pricing
Reference pricing from DrugBank. Prices are indicative and may not reflect current UK costs.
Source: DrugBank. Used under CC BY-NC 4.0 academic licence for non-commercial purposes.
Patent information
All patents expired, 1 expired
Source: DrugBank · CC BY-NC 4.0. Patent data sourced from national patent offices. Expiry dates may not reflect extensions, regulatory exclusivity periods, or legal challenges.
DrugBank citations
If you use DrugBank data in your research, please cite the following publications: